Stocks News

LAST PRICE
41.9600
TODAY'S CHANGE (%)
Trending Down-1.0500 (-2.4413%)

Bid / Lots
41.8000/ 1
Ask / Lots
44.5000/ 4
Open / Previous Close
43.2100 / 43.0100
Day Range
Low 41.4800
High 43.3200
52 Week Range
Low 31.5200
High 54.9800
Volume
842,499
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference, from 5 hours ago by GlobeNewswire
  5 hours ago by GlobeNewswire
  Companies Mentioned: RARE
- Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference, from 5 hours ago by Dow Jones
  5 hours ago by Dow Jones
  Companies Mentioned: RARE
  
  Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference
  
  NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Eric Crombez, M.D., the company's chief medical officer and executive vice president, will participate in a fireside at Bank of America's 2024 Healthcare Conference on Tuesday, May 14, 2024, at 1:40 p.m. PT.
Yesterday
- DJ Ultragenyx Pharma Is Maintained at Buy by Canaccord Genuity, from 1:45PM ET on Monday May 06, 2024 by Dow Jones
  1:45PM ET on Monday May 06, 2024 by Dow Jones
  Companies Mentioned: RARE
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RARE/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 06, 2024 13:45 ET (17:45 GMT)
May 3, 2024
- DJ Ultragenyx Pharma Price Target Maintained With a $107.00/Share by Cantor Fitzgerald, from 11:24AM ET on Friday May 03, 2024 by Dow Jones
  11:24AM ET on Friday May 03, 2024 by Dow Jones
  Companies Mentioned: RARE
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RARE/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 03, 2024 11:24 ET (15:24 GMT)
- --Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating, from 9:56AM ET on Friday May 03, 2024 by MT Newswires
  9:56AM ET on Friday May 03, 2024 by MT Newswires
  Companies Mentioned: RARE
  09:56 AM EDT, 05/03/2024 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contac...

Today
- Baird Adjusts Price Target on Axsome Therapeutics to $112 From $108, Maintains Outperform Rating, from 12 hours ago by MT Newswires
  12 hours ago by MT Newswires
  Companies Mentioned: AXSM
- Insmed To Present at the BofA Securities Health Care Conference 2024, from 13 hours ago by PR Newswire
  13 hours ago by PR Newswire
  Companies Mentioned: INSM
Yesterday
- Axsome Therapeutics Q1 Loss Widens, Revenue Declines -- Shares Advance Pre-Bell, from 7:33AM ET on Monday May 06, 2024 by MT Newswires
  7:33AM ET on Monday May 06, 2024 by MT Newswires
  Companies Mentioned: AXSM
- -- Earnings Flash (AXSM) AXSOME THERAPEUTICS Posts Q1 Revenue $75M, vs. Street Est of $72.9M, from 7:01AM ET on Monday May 06, 2024 by MT Newswires
  7:01AM ET on Monday May 06, 2024 by MT Newswires
  Companies Mentioned: AXSM
- Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update, from 7:00AM ET on Monday May 06, 2024 by GlobeNewswire
  7:00AM ET on Monday May 06, 2024 by GlobeNewswire
  Companies Mentioned: AXSM
May 3, 2024
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), from 8:00AM ET on Friday May 03, 2024 by PR Newswire
  8:00AM ET on Friday May 03, 2024 by PR Newswire
  Companies Mentioned: INSM
May 2, 2024
- Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance, from 12:13PM ET on Thursday May 02, 2024 by MT Newswires
  12:13PM ET on Thursday May 02, 2024 by MT Newswires
  Companies Mentioned: GMAB
May 1, 2024
- Axsome Therapeutics Recognizes May as Mental Health Awareness Month, from 7:00AM ET on Wednesday May 01, 2024 by GlobeNewswire
  7:00AM ET on Wednesday May 01, 2024 by GlobeNewswire
  Companies Mentioned: AXSM
- Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024, from 7:00AM ET on Wednesday May 01, 2024 by GlobeNewswire
  7:00AM ET on Wednesday May 01, 2024 by GlobeNewswire
  Companies Mentioned: FOLD
Apr 30, 2024
- AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm, from 9:00PM ET on Tuesday Apr 30, 2024 by GlobeNewswire
  9:00PM ET on Tuesday Apr 30, 2024 by GlobeNewswire
  Companies Mentioned: AXSM

Ultragenyx Pharmaceutical Inc
NASDAQ:RAREUnited States

Search Criteria

Today

Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference, from 5 hours ago by GlobeNewswire

Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference, from 5 hours ago by Dow Jones

Yesterday

DJ Ultragenyx Pharma Is Maintained at Buy by Canaccord Genuity, from 1:45PM ET on Monday May 06, 2024 by Dow Jones

May 3, 2024

DJ Ultragenyx Pharma Price Target Maintained With a $107.00/Share by Cantor Fitzgerald, from 11:24AM ET on Friday May 03, 2024 by Dow Jones

--Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating, from 9:56AM ET on Friday May 03, 2024 by MT Newswires

Peers Headlines

Today

Baird Adjusts Price Target on Axsome Therapeutics to $112 From $108, Maintains Outperform Rating, from 12 hours ago by MT Newswires

Insmed To Present at the BofA Securities Health Care Conference 2024, from 13 hours ago by PR Newswire

Yesterday

Axsome Therapeutics Q1 Loss Widens, Revenue Declines -- Shares Advance Pre-Bell, from 7:33AM ET on Monday May 06, 2024 by MT Newswires

-- Earnings Flash (AXSM) AXSOME THERAPEUTICS Posts Q1 Revenue $75M, vs. Street Est of $72.9M, from 7:01AM ET on Monday May 06, 2024 by MT Newswires

Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update, from 7:00AM ET on Monday May 06, 2024 by GlobeNewswire

May 3, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), from 8:00AM ET on Friday May 03, 2024 by PR Newswire

May 2, 2024

Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance, from 12:13PM ET on Thursday May 02, 2024 by MT Newswires

May 1, 2024

Axsome Therapeutics Recognizes May as Mental Health Awareness Month, from 7:00AM ET on Wednesday May 01, 2024 by GlobeNewswire

Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024, from 7:00AM ET on Wednesday May 01, 2024 by GlobeNewswire

Apr 30, 2024

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm, from 9:00PM ET on Tuesday Apr 30, 2024 by GlobeNewswire